Exploring unique solutions for diabetes biopharmaceuticals
Cellnuo focuses on the development of biopharmaceuticals for diabetes, using gene engineering methods to produce GLP-1 and insulin-based biopharmaceuticals, and exploring new drugs and treatments for diabetes.Recombinant human insulin
We are at the forefront of research on stem cell therapy.
Cellnuo is actively exploring stem cell therapy and gut microbiome therapy, with support from laboratories in Germany and the United States for related cutting-edge technologies.
rhEGF
Production of various bio-based API, stable and reliableCellnuo Biologics provides high-quality, highly stable recombinant proteins, enzymes and other factor-based products, as well as high-level technical services to global pharmaceutical companies, culture medium companies and research institutions.
Insulin Degludec API
Peptide / Protein API
Liraglutide, Recombinant insulin aspart, recombinant insulin degludec,， Weekly insulin，GLP-1/GIP receptor dual agonist
Cell culture media / CGT products
Recombinant human insulin, EGF, FGF2, IGF-1 LR3, Transferrin, Noggin / Supernuclease, T7RNA polymerase，Cas9 enzyme
Protease
Recombinant Trypsin, Recombinant Aprotinin, Recombinant Enterokinase, Recombinant Proteinase K, Aminopeptidases